Journal of Neuro-Oncology

, Volume 84, Issue 2, pp 147–157

Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-κB and Notch1 signaling

  • Xiaohua Gao
  • Dorrah Deeb
  • Hao Jiang
  • Yongbo Liu
  • Scott A. Dulchavsky
  • Subhash C. Gautam
Lab investigation-human/animal tissue


Glioblastomas are high-risk primary brain tumors that are generally unresponsive or only weakly responsive to the currently available antineoplastic agents. Thus novel therapeutic strategies and agents are urgently needed to treat these incurable cancers. Oleanolic acid and ursolic acid are naturally occurring triterpenoids that have been used in traditional Asian medicine as anti-inflammatory and anti-cancer agents. Recently, synthetic oleanolic acid triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO) and its C-28 methyl ester (CDDO-Me) and C-28 imidazole (CDDO-Im) derivatives have been shown to exhibit potent antitumor activity against diverse types of tumor cell lines, including leukemia, multiple myeloma, osteosarcoma, breast, lung, and pancreatic cancer cell lines; however, the anticancer activity of these agents for brain tumors has not been reported. In the present study, we investigated the apoptosis-inducing activity of CDDOs in glioblastoma (U87MG, U251MG) and neuroblastoma (SK-N-MC) cell lines. Cell growth/viability (MTS) and cytotoxicity (LDH release) assays demonstrated that glioblastoma cell lines are least sensitive to CDDO, but are highly sensitive to CDDO-Me and CDDO-Im at concentrations of 2.5–10 μM. CDDO-Im and CDDO-Me were equipotenent in their growth inhibitory activity. The primary mode of tumor cell destruction was apoptosis as demonstrated by significant increase in the number of hypo-diploid (sub-G0) cells and annexin V-FITC binding. Induction of apoptosis was associated with the activation of procaspases-3, -8, and -9, mitochondrial depolarization and the release of cytochrome c from mitochondria. Furthermore, CDDO-Me inhibited the levels of anti-apoptotic and prosurvival p-Akt, NF-κB (p65) and Notch1 signaling molecules. These studies provide rationale for clinical evaluation of these novel agents for the management of lethal brain neoplasms.


Triterpenoids Glioblastoma Apoptosis p-Akt NF-κNotch1 


  1. 1.
    Hosli P, Sappino A, de Tribolet N, Dietrich P (1998) Ann Oncol 9:589–600Google Scholar
  2. 2.
    DeAngelis LM, Burger PC, Green SB, Caironcross JG (1998) Malignant glioma: who benefits from adjuvant chemotherapy. Ann Neurol 44:691–695PubMedCrossRefGoogle Scholar
  3. 3.
    Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Caner 71:2585–2597CrossRefGoogle Scholar
  4. 4.
    Kim TS, Halliday AL, Hedley-Whyte ET, Convey K (1991) Correlates of survival and the Dumas-Duport grading system for astrocytomas. J Neurosurg 74:27–37PubMedGoogle Scholar
  5. 5.
    Shapiro WR, Green SB, Burger PC, Maheley MS Jr, Selker RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J Jr, Strike TA et al (1989) Randomized trials of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant gliomas. J Neurosurg 71:1–9PubMedCrossRefGoogle Scholar
  6. 6.
    Arceci RJ (1995) Mechanism of resistance to therapy and tumor survival. Curr Opin Hematol 2:268–274PubMedCrossRefGoogle Scholar
  7. 7.
    Denmeade SR, Lin XS, Isaacs JT (1996) Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 28:251–265PubMedCrossRefGoogle Scholar
  8. 8.
    Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013–2026Google Scholar
  9. 9.
    Rieger J, Naumann U, Glaser T, Ashkenazi A, Weller M (1998) APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett 427:124–128PubMedCrossRefGoogle Scholar
  10. 10.
    Knight MJ, Riffkin CD, Muscat AM, Ashley DM, Hawkins CJ (2001) Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 20:5789–5798 PubMedCrossRefGoogle Scholar
  11. 11.
    Pollack IF, Erff M, Ashkenazi A (2001) Direct stimulation of apoptotic signaling by soluble apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 7:1362–1369PubMedGoogle Scholar
  12. 12.
    Sporn MB, Suh N (2000) Chemoprevention of cancer. Carcinogenesis 21:525PubMedCrossRefGoogle Scholar
  13. 13.
    Huang MT, Ho CT, Wang ZY, Ferraro T, Lou YR, Stauber K, Ma W, Georgiadis C, Laskin JD, Conney AH (1994) Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 54:701PubMedGoogle Scholar
  14. 14.
    Nishino H, Nishino A, Takayasu J, Hasegawa T, Iwashima A, Hirabayashi K, Iwata S, Shibata S (1988) Inhibition of the tumor-promoting action of 12-O-tetradecanoylphorbol-13-accetate by some oleanane-type triterpenoid compounds. Cancer Res 48:5210PubMedGoogle Scholar
  15. 15.
    Ryu SY, Oak MH, Yoon SK, Cho DI, Yoo GS, Kim TS, Kim KM (2000) Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med 66:358PubMedCrossRefGoogle Scholar
  16. 16.
    Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF et al (1998) Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Biorg Med Chem Lett 8:2711CrossRefGoogle Scholar
  17. 17.
    Suh N, Honda T, Finlay HJ, Barchowsky A, Williams C, Benoit NE, Xie QW, Nathan C, Gribble GW, Sporn MB (1998) Triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxigenase (COX-2) in mouse macrophages. Cancer Res 58:717PubMedGoogle Scholar
  18. 18.
    Honda T, Rounds BV, Bore L, Favaloro FG, Gibble GW, Suh N, Wang Y, Sporn MB (1999) Novel synthetic oleanane triterpenoids: a series of highly active inhibitors of nitric oxide production in mouse macrophages. Bioorg Chem Lett 9:3429CrossRefGoogle Scholar
  19. 19.
    Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB (1999) A novel synthetic oleanane triterpenoid, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 59:336–341PubMedGoogle Scholar
  20. 20.
    Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M (2002) Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood 99:326–335PubMedCrossRefGoogle Scholar
  21. 21.
    Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB (2006) A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res12:1828–1838CrossRefGoogle Scholar
  22. 22.
    Ikeda T, Sporn M, Honda T, Gribble GW, Kufe D (2003) The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. Cancer Res 63(17):5551–5558PubMedGoogle Scholar
  23. 23.
    Konopleva M, Tsao T, Estrov Z, Lee RM, Wang RY, Jackson CE, McQueen T, Monaco G, Munsell M, Belmont J, Kantarjian H, Sporn MB, Andreeff M (2004) The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia. Cancer Res 64:7927–7935PubMedCrossRefGoogle Scholar
  24. 24.
    Ito Y, Pandey P, Sporn MB, Datta R, Kharbanda S, Kufe D (2001) The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. Mol Pharmacol 59:1094–1099PubMedGoogle Scholar
  25. 25.
    Konopleva M, Contractor R, Kurinna SM, Chen W, Andreeff M, Ruvolo PP (2005) The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells. Leukemia 19:1350–1354PubMedCrossRefGoogle Scholar
  26. 26.
    Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB (2003) Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 63:1371–1376PubMedGoogle Scholar
  27. 27.
    Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S (2005) 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. Mol Pharmacol 68:119–128PubMedGoogle Scholar
  28. 28.
    Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY (2004) c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res 64:7570–7578PubMedCrossRefGoogle Scholar
  29. 29.
    Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, Gribble GW, Leesnitzer LM, Stimmel JB, Willson TM, Rosen E, Sporn MB (2003) The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9:2798–2806PubMedGoogle Scholar
  30. 30.
    Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC (2005) Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 65:4799–4808PubMedCrossRefGoogle Scholar
  31. 31.
    Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, Brat DJ, Perry A, Eberhart CG (2004) Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 65:2353–2363CrossRefGoogle Scholar
  32. 32.
    Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA (2005) Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 65:2353–2363PubMedCrossRefGoogle Scholar
  33. 33.
    Sun X-M, MacFarlane M, Zhuang J, Wolf BB, Green DR, Cohen GM (1999) Distinct caspase cascades are initiated in receptor-mediated and chemical-induced apoptosis. J Biol Chem 27:4053–5060 Google Scholar
  34. 34.
    Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 28:1305–1308CrossRefGoogle Scholar
  35. 35.
    Luo X, Budihardjo I, Zou H, Slaughter C, Wang X (1998) Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 9:481–490CrossRefGoogle Scholar
  36. 36.
    Marte BM, Downward J (1997) PKB/Akt: connecting phosphoinositide3-kinase to cell survival and beyond. Trends Biochem Sci 22:355–358PubMedCrossRefGoogle Scholar
  37. 37.
    Altomare DA, Testa JR (2005) Perturbations of the Akt signaling pathway in human cancer. Oncogene 24:7455–7464PubMedCrossRefGoogle Scholar
  38. 38.
    Karin M, Cao Y, Greten FR, Li Z-W (2002) NF-κB in cancer. From innocent bystander to major culprit. Nature Rev Cancer 2:301–310Google Scholar
  39. 39.
    Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell 91:231–241PubMedCrossRefGoogle Scholar
  40. 40.
    Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Standbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318–1321PubMedCrossRefGoogle Scholar
  41. 41.
    Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857–868PubMedCrossRefGoogle Scholar
  42. 42.
    Baeurele PA, Henkel T (1994) Function and activation of NF-κB in the immune system. Annu Rev Immunol 12:141–179Google Scholar
  43. 43.
    Mayo MW, Baldwin AS (2000) The transcription factor NF-κB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470:M55–M62PubMedGoogle Scholar
  44. 44.
    Weaver KD, Yeyeodu S, Cusack JC Jr, Baldwin AS Jr, Ewend MG (2003) Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 61:187–196PubMedCrossRefGoogle Scholar
  45. 45.
    Cusack JC Jr (2003) Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 10:852–862PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Xiaohua Gao
    • 1
  • Dorrah Deeb
    • 1
  • Hao Jiang
    • 2
  • Yongbo Liu
    • 1
  • Scott A. Dulchavsky
    • 1
  • Subhash C. Gautam
    • 1
  1. 1.Department of SurgeryHenry Ford Health SystemDetroitUSA
  2. 2.Department of NeurologyHenry Ford Health SystemDetroitUSA

Personalised recommendations